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A little GC, like a glass of wine, may benefit many people,
whereas a high dose of GC, like a bottle of wine, is harmful to all
A
t the 2003 meeting of the
American College of
Rheumatology (ACR) a debate
on the advantages and disadvantages
of glucocorticoids (GCs) in the treat-
ment of early and late rheumatoid
arthritis (RA) was held, with some
authors putting the case for, and others
the case against, such treatment (pre-
sentations now available online: http://
www.rheumatology.org). Some new
data emerged, and this paper sum-
marises the arguments and the existing
and new data.
HISTORY
Hench was awarded the Nobel prize in
1950 for the discovery of GCs and their
effect in established RA. However, sub-
sequently disillusionment with GCs set
in, caused by the rapid appearance of
unacceptable side effects of long term
high dose treatment, and loss of efficacy
at lower dosing. The dogma became that
treatment with systemic GCs caused
only temporary symptomatic relief, led
to habituation with danger of ever
increasing doses necessary to maintain
effect, and that chronic treatment uni-
versally caused unacceptable side
effects. Therefore, such treatment was
often only considered as a last resort. An
associated idea was that RA was in most
cases a benign disease, which, although
incurable, caused significant disability
in only a minority of cases. The combi-
nation of these ideas caused most
rheumatologists to limit treatment to
traditional schemes that emphasised
rest, lifestyle adjustment, non-steroidal
anti-inflammatory drugs (NSAIDs), and
spa treatment. In unresponsive cases
antirheumatic drugs such as intra-
muscular gold were advised. A paradigm
shift was initiated by Wilske and Healey,
who argued that the pyramid should
be inverted and aggressive treatment
should be started early.1 This was based
on the appearance of long term outcome
studies that recorded the dismal prog-
nosis of many patients when followed
up for a long enough time. With this
shift, the door was opened a crack to
allow re-examination of the old dogma.
MECHANISMS, USE, AND
DOSAGES
To better understand published reports
on the effects of GCs in RA, it is
important to recognise two different
aspects of the disease process. The first
aspect is clinical symptoms of inflam-
mation, which may be inhibited by
NSAIDs. This process is partly due to
infiltration of the synovial tissue by
lymphocytes. The second aspect is ero-
sive progression of the disease, which
can be inhibited by disease modifying
antirheumatic drugs (DMARDs) such as
methotrexate and tumour necrosis fac-
tor a blockers. This process is partly due
to synovial infiltration by macrophages.
Both processes are closely linked, but
partially independent and both pro-
cesses may respond differently to differ-
ent interventions. GCs seem to influence
the inflammatory process especially
during the first months of treatment,
while effects on erosions become evi-
dent after a more prolonged period of
time.
‘‘Glucocorticoids act on the inflam-
matory process immediately and on
erosions only after a longer period
of time’’
GCs have a profound effect on the
immune system, interfering with the
cytokine network and inflammatory
enzymes, and with adhesion molecules,
permeability factors, cellular function,
and survival. GCs are still the most
effective anti-phlogistic and immune
suppressive substances known.2 In early
RA, and even in some patients before
they develop RA, an insufficiency of the
hypothalamic pituitary adrenal (HPA)
axis has been documented. Discussion is
still continuing as to whether or not this
is the ‘‘chicken or the egg’’. In any case
it is evident from many studies that
cortisol levels found in patients with RA
are insufficient to control the continu-
ing inflammatory process.3 4
In America up to 75% of patients
with RA use glucocorticoids regularly,
concomitantly with other drugs.5 6 In
Europe the percentage is around 25%,
although the role of GCs was reassessed
in Europe during the past decade.7 In
the third world, GC use is very common,
as they are one of the only cheap and
widely available drugs; they are often
sold over the counter.8 The official views
(as expressed in textbooks on both sides
of the Atlantic) are similar and consis-
tent in their opposition to GC treatment.
The 2002 update of the guidelines for
the management of rheumatoid arthritis
of the ACR states: ‘‘Low dose oral
glucocorticoids (10 mg or less of pre-
dnisone daily) are highly effective at
relieving symptoms in patients with
active RA. A patient disabled by active
polyarthritis may experience marked
and rapid improvement in functional
status within days following initiation
of glucocorticoids. Frequently, disabling
synovitis recurs when glucocorticoids
are discontinued, even in patients who
are receiving combination therapy with
one or more DMARDs. Therefore, many
patients with RA are functionally
dependent on glucocorticoids and con-
tinue them long term’’.9
What is considered to be a low dose of
GCs? In patients with active RA partici-
pating in most clinical trials, a mean
dosage of glucocorticoids of the order of
7 mg/day is found.5–7 In descriptive
cohort studies of patients with long-
standing RA many patients have less
active disease and the mean dosage
of glucocorticoids is of the order of
3–5 mg/day, implying that some
patients do very well on even a very
low dose of GCs. Recently, a consensus
meeting on standardisation of the
nomenclature of GCs in rheumatic dis-
eases was held. In the meeting report
definitions for the dosage, based on
pathophysiological and pharmaco-
kinetic data, were suggested: ‘‘low dose’’
was defined as 7.5 mg or less predni-
sone equivalent a day, a ‘‘medium dose’’
as 7.5–30 mg daily, and a ‘‘high dose’’
was defined as above 30 mg daily.10
DOGMA AND FACTS: EFFICACY
Clinical signs of inflammation
It is astonishing to note the paucity of
published data that can stand up to
critical assessment by current standards.
In 1997, a Cochrane review concluded
on the basis of seven studies and a
total of 253 patients: ‘‘Although our
findings are based on very few con-
trolled studies, they generally uphold
the widely held belief that corticoster-
oids, when administered for periods of
approximately 6 months, are effective
for the treatment of RA’’.11 This conclu-
sion supports the widespread use of
GCs, even though guidelines are more
negative.
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More recent trials and follow up
studies have added important data to
our still limited understanding. One
hundred and one patients with estab-
lished RA co-treated with conventional
DMARDs were included in a placebo
controlled trial that studied 30 mg pred-
nisone daily tapered to 7.5 mg in
three weeks, and further tapered
according to clinical activity.12 More
rapid onset of effect in the GC group
was found, but the difference between
treatment groups was lost after a few
months, although effects on Health
Assessment Questionnaire (HAQ) and
grip strength persisted. The Utrecht
group performed a placebo controlled
trial of 10 mg prednisone as monother-
apy in early (,1 year), DMARD naive
patients (total, n = 81).13 The duration
of the trial was two years; rescue
sulfasalazine was allowed after six
months, and more than half of the
patients in each group started this drug.
‘‘Cochrane review supports the
use of GCs, though guidelines are
more negative’’
At six months, improvement in dis-
ease activity was more rapid in the GC
group, despite lower use of intra-articu-
lar injections and NSAIDs. However,
these differences were no longer sig-
nificant at one year and later, though
the use of NSAIDs and intra-articular
injections stayed lower in the GC group.
Together with very similar results from
the UK,14 one can conclude that low to
medium dose prednisolone (up to
10 mg/day) added to other DMARDs
leads to rapid clinical response that in
general does not persist beyond six
months.
Radiographic damage
From the late 1950s onwards studies
have pointed to an effect on radio-
graphic damage. Although the early
studies were well designed, the results
are not so easily summarised because
scoring was not standardised. A
Cochrane review is currently underway;
it will include over 700 patients in about
10 studies.12–14 The overwhelming signal
is that GCs retard radiological progres-
sion. One of the studies included is the
COBRA trial,15 for which data on long
term follow up were recently pub-
lished.16 This trial compared the combi-
nation of step-down prednisolone
(60 mg/day down to 7.5 mg/day in
seven weeks), methotrexate, and sulfa-
salazine with sulfasalazine alone: clin-
ical benefits were no longer significant
after GCs were stopped, but differences
in damage progression were evident up
to one year after stopping GCs. It must
be emphasised that this was a trial with
an active treatment control group and
that the patients in this group
responded adequately to sulfasalazine
as expected. In the long term follow up
of COBRA (mean 4.5 years) the yearly
rate of progression remained signifi-
cantly and relevantly lower in the
combination group (5.4 Sharp points
per year v 8.6 in the sulfasalazine group)
despite equal treatment, disease activity,
and HAQ in both groups. The fact that
the progression lines are not parallel
(suggesting the initial advantage is
maintained) but actually diverge sug-
gests true disease modification of the
combination schedule, with GCs in this
dose acting either as a specific disease
modifier, or as the agent working
generically by inducing the rapid initial
suppression of disease activity. In the
Utrecht study, the only recent study in
which GCs were used as monotherapy, a
significant decrease in radiographic pro-
gression was also seen in the patients,
starting at six months.13 Comparable
data were reported in the UK study in
patients with RA in whom GCs were
added to other antirheumatic treat-
ment.14 In conclusion, low dose GCs
clearly decrease radiological progres-
sion.
Efficacy summary
GCs are still the most effective anti-
phlogistic and immune suppressive sub-
stances known. When given for periods
of about six months, GCs are effective in
reducing signs and symptoms of inflam-
mation in RA; after that time the
symptomatic effect wanes when GCs
are used as co-medication with
DMARDs, though co-medication of
NSAIDs, use of intra-articular injec-
tions, and other treatments are lower
when GCs are continued. Apart from
this symptomatic effect, it has now
become clear that GCs can reduce the
progression of erosions in patients with
RA, an effect that even seems to persist
when GC treatment is stopped.
DOGMA AND FACTS: TOXICITY
There is no question that GCs, especially
in high doses and continued for longer
periods, can cause devastating morbid-
ity. Although the textbooks are full of
the ‘‘well known’’ side effects of GCs,
we actually know little of their inci-
dence, prevalence, and true impact; and
almost nothing about the relation of
these effects with different dosing sche-
dules. The quality of evidence on toxicity
is even less than that for efficacy. Table 1
lists the toxicities typically associated
with chronic GC use. Potential side
effects can be divided into those that
are possibly preventable and ones that
are largely idiosyncratic and typically
not preventable. Although observational
studies of serious GC adverse effects
(AEs) identify fractures and ocular
toxicity as among the most prevalent,17
patients often worry more about less
serious, albeit more apparent, sequelae
such as cushingoid facies, skin thinning,
and ecchymoses. Catabolic effects on
the skin during systemic GC treatment
include cutaneous atrophy, resulting
from GC effects on keratinocytes and
fibroblasts. Decreased vascular struc-
tural integrity is probably a key deter-
minant of purpura and easy bruisability
in GC treated patients.18 These effects
were reported to affect over 5% of those
exposed to 5 mg or more prednisone
equivalent for one year or longer.19 At
the lower dose range of GCs (below the
physiological threshold) commonly used
by American doctors to manage RA,
change in personal appearance is an
uncommon outcome. However, the tra-
ditionally assumed physiological thresh-
old (about 7.5 mg/day of prednisone)
may be overestimated20; thus, even very
low doses may exceed it and lead to
these AEs.
Bone
Of all serious AEs attributed to GCs,
bone loss leading to fractures provokes
the most trepidation among knowledge-
able doctors. Long term follow up of
women in the large Arthritis and
Medical Information System
(ARAMIS) cohort identified a risk of
about 33% of having a fracture after five
years of follow up on an average GC
dose of only 8.6 mg/day.21 In a large
Norwegian cohort current GC use was
associated with loss of bone mineral
density (BMD) at both the total hip
(adjusted odds ratio (aOR) = 2.6) and
spine (aOR = 2.7).22 Although factors
other than BMD predispose to fracture
risk in these patients, BMD of both the
spine and hip is a significant indepen-
dent predictor of vertebral fracture
among GC users.23 Negative effects on
bone formation, in contrast with heigh-
tened bone resorption, appear to be
most central to GC induced osteoporo-
sis.24
‘‘Some data suggest that GCs may
even benefit the bones of patients
with RA’’
Despite this pathogenic rationale and
accumulating evidence from observa-
tional studies on GC risk to bone, some
data suggest that GCs may actually
benefit bones in patients with RA.25
This benefit may be brought about by
decreasing the disease activity, promot-
ing beneficial weightbearing activity
and a reduction in proinflammatory
cytokines deleterious to bone.26 These
dissenting opinions on the toxicity of
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glucocorticoids to bone have been
strengthened by mixed and inconclusive
results from recent large randomised
controlled trials (RCTs) of GC use in RA.
It is important to note, however, that to
date GC RCTs have been significantly
underpowered to detect even modest
differences in fractures between
patients receiving and not receiving
GCs. In addition to doctors’ concerns
and beyond the disability, morbidity,
and attributable mortality of fractures,
patients receiving GCs greatly fear this
complication. When the preferences of a
patient with RA for GC sequelae were
evaluated using hypothetical decision
scenarios, serious fractures were rated
as the worst of all possible GC com-
plications (preference value of 0.55;
values are anchored at 0 = death and
1 = current health).27 Although the
osteoporosis complications of GC use
are a major reason for questioning their
role in RA management, the advent of
effective and safe prevention for GC
induced osteoporosis has partially ame-
liorated this problem. The ACR and a
number of other specialty based con-
sensus groups have issued guidelines or
position statements advocating a much
more aggressive approach to GC induced
osteoporosis prevention.28
In addition to periodic bone mass
measurement, American, Canadian, and
Australian guidelines also advocate
aggressive use of aminobisphophonate
drugs such as alendronate or risedro-
nate. Although the indications for the
use of bisphosphonate vary based on
these different guidelines, patients
expected to require prolonged supra-
physiological GC doses, those with
existing low bone mass (T score ,21.0
in some and less than 21.5 in other
guidelines), and postmenopausal women
are high risk groups that should receive
bisphosphonates sooner rather than
later. Other therapeutic options such as
calcitonin, oestrogen, testosterone, and
possibly, thiazide diuretics (early in the
course of GC use) have more limited
scientific support. Despite the clear effi-
cacy of bisphosphonates to significantly
increase bone mass and lower vertebral
fracture risk (study designs limited by
sample size), bisphosphonates do not
cure GC induced osteoporosis. Further-
more, therapeutic costs and the need for
increasing polypharmacy limit enthu-
siasm for a combined approach of GCs
and bisphosphonates in RA.29
In summary, although some treat-
ment is available to prevent bone
complications of GCs, these complica-
tions are still of concern at even low
doses of GCs.
Another less common bone complica-
tion of GCs is osteonecrosis (ON).
Although ON may have a similar patho-
genesis to that of GC induced osteo-
porosis, it is very unusual among
patients treated with lower doses, such
as in RA. An incidence of ON of ,3%
was seen at replacement doses and
clinically significant ON is seldom
reported in patients with RA receiving
GC doses below 20 mg/day.30
Gastrointestinal
Gastrointestinal (GI) AEs of GCs alone
are less severe than those seen when
non-selective NSAIDs are used.
However, when GCs are used in combi-
nation with NSAIDs, a synergistic
increased risk of GI AEs is observed. In
a Medicare database 1400 patients with
different inflammatory diseases receiv-
ing GC treatment were evaluated: the
relative risk of a peptic ulcer or GI bleed
was 2.0, but multivariate analysis
showed that concomitant use of
NSAIDs explained this increased risk,31
indicating that GCs alone have no
increased risk for GI events. In an
observational study of 566 patients with
RA using steroids (mean duration of use
5.1 years; mean prednisone dose
6.84 mg/day) compared with 253 con-
trols followed up over slightly more than
eight years, even low dose prednisone
(,5.0 mg/day) was associated with an
increased risk of GI ulcerations, with an
OR of 1.8 after a mean of 1.5 years of
use.32 This OR increased slightly, up to
an OR of 2.1 when GCs were used for
more than five years.
Eye
Similar to bone disease, cataracts are
ubiquitous with prolonged GC treat-
ment. Posterior subcapsular cataracts,
although less common than senile or
cortical cataracts in a population, are
the type of cataracts most typically
associated with GC treatment.33
Biochemically, GC-lysine adducts caus-
ing lens particles to form, and inhibition
of the sodium-potassium pump increas-
ing the water content of the lens may
explain this complication. Although
there have been few comprehensive
analyses of this risk, posterior subcap-
sular cataracts may develop in as few as
two years on as little as 5 mg/day of
prednisone. Of interest, a population
based study has also detected a .2.5-
fold increased risk of cortical cataracts
in GC users compared with non-users.34
Inhaled GCs have been associated with
increased risk of cataracts, emphasising
a potential effect with even very low
doses.35 Overall, limited data on gluco-
corticoids and cataracts seem to support
the association of GCs and cataracts, but
these data also highlight the need for
more research into this toxicity.
Cardiovascular
Although acute hypertension and lipo-
protein perturbations with GCs may
ultimately result in a higher risk of
cardiovascular disease,36 37 investigation
into this topic is particularly confounded
by RA disease activity. An association of
RA with a higher risk of cardiovascular
disease may relate to a direct deleterious
impact of prolonged inflammation on
cardiovascular disease. Because anti-
inflammatory agents may lower the risk
of cardiovascular disease, long term data
are needed to determine whether a GC
effect on atherosclerotic disease is inde-
pendent of RA. Prior data from retro-
spective cohorts have attributed GC use
to heightened overall mortality,38
although confounding by indication is
problematic in these types of observa-
tional studies. Recent data from cohorts
show that RA disease activity alters the
blood lipid profile unfavourably, and
treatment (including GC treatment) can
reverse these changes.39
Glucose metabolism
It takes only a few weeks before
hyperglycaemia can occur when using
GCs and there is both a dose-response
and inverse duration effect for this end
point. At doses of 1–7.9 mg prednisone
daily, the OR for hyperglycaemia is 1.8;
this rises progressively to an OR of 7
when the dose of prednisone is 25 mg
daily or more. The OR of requiring
treatment for hyperglycaemia is 1.7
during the first 45 days of corticosteroid
use, falls to 1.3 between 46 and 90 days,
and is merely 1.1 beyond that point.40 As
this is based on an observational cohort
study, a decrement in risk over time is
logical, as GCs will be stopped if
hyperglycaemia is found and hypergly-
Table 1 Potential glucocorticoid toxicity
Potentially preventable Not preventable
Acne vulgaris Accelerated atherosclerotic vascular disease
Congestive heart failure and fluid retention Cataracts
Diabetes mellitus Mood change
Glaucoma Myopathy
Hypertension Osteonecrosis
Osteoporosis Serious infection
Peptic ulcer disease Skin bruising/thinning
Sleep disturbances and memory effects Weight gain
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caemia was found early in GC use in this
study, probably because serum glucose
was monitored. The development of
overt diabetes in patients using low
dose GCs is rare.
Infections
In an American evaluation of 566
patients with RA receiving GCs, a
22.4% incidence of infections versus
13% in the controls was observed.32
The OR for an infection was 1.72 when
steroids were used for six months or
longer. This result, however, contrasts
with the results from a review on
infections complications in patients tak-
ing GCs.41 In five studies quoted in the
review, there was no increase in infec-
tion rate among rheumatic patients
given up to 8 mg GCs daily, although
the duration of use of the steroids in
those studies was not delineated.
Another review stated that GC doses
>10 mg daily (total dose .700 mg) for
at least 3–4 weeks were needed before
there was an increased incidence of
infection.19 42 Infections are probably
increased in GC users, although rela-
tively insignificantly for patients receiv-
ing low dose GCs for RA.
HPA axis
There is little doubt that higher doses of
prednisone over long periods can cause
HPA axis suppression and many pub-
lished reports attest to this effect.43 On
the other hand, the best data relating to
very low doses of prednisone come from
a meta-analysis comparing the effects of
intranasal steroid preparations, which
used oral prednisone as a comparator.43
In an analysis of 13 studies and using
8 00 am serum cortisol as a measure of
HPA suppression, it appears that doses
,8 mg/day prednisolone (the exact dose
is hard to discern from the figure) will
suppress 8 00 am cortisol. These data
show that low doses of GCs, in the range
of the doses often used when treating
RA, can regularly cause HPA suppres-
sion, although the duration of such
treatment required for such an effect
to occur is not explicitly defined. To
make these data more difficult to inter-
pret, it has been suggested that RA itself
has an influence on the HPA axis.2
Mental functioning
The doses of prednisone used to treat RA
have not usually been associated with
steroid psychosis, so this aspect of the
side effects of GC in early RA will not be
considered further here.44 However, GCs
do seem to have an effect on neuronal
death.45 When GCs are used, transloca-
tion of pre-existing glucose cell surface
receptors to the intracellular environ-
ment seems to occur, resulting in 25–
30% inhibition of glucose transport into
cells. This accelerates the usual decline
in ATP concentrations after ischaemia or
hypoglycaemia. This, in turn, decreases
the ability to inhibit neuronal insults.
This theoretical construct has been
carried into a study of normal volun-
teers given 10 mg oral hydrocortisone in
a single blind study.46 Hippocampal
dependent functions such as declarative
memory and spatial thinking, as well as
non-hippocampal dependent measures
such as procedural thinking were tested.
The hippocampal dependent functions
were found to be impaired. In another
test of mental functioning, paired asso-
ciation word recall and consolidation of
verbal learning (hippocampal depen-
dent functions) were impaired at the
time of hydrocortisone infusions and
four days later.47 These experiments in
normal volunteers were later tested in
patients with RA who had been receiv-
ing GCs for more than one year and
compared with the results for controls.48
Once again, hippocampal functioning
(recall of explicit facts) was impaired,
while non-hippocampal functioning
(procedural memory) was not.
Toxicity summary
An increasing number of clinical trials
comparing GC users with non-users
inform us about the short and moderate
term AEs in GC users. There are credible
data that even low dose GCs given for
weeks to months can have significant
toxicity in numerous areas, including GI
ulcerations and bleeding when given
together with NSAIDs, an increased
incidence of infections, an increased
incidence of hyperglycaemia, a predis-
position to glaucoma, suppression of the
HPA axis, abnormalities in recall and
mental functioning, and skin ecchy-
moses and thinning. Despite this
increasing knowledge, longer term data
are badly needed to assess the impact of
this most commonly used treatment.
Bone loss and cataracts are the compli-
cations most well validated, whereas
other long term AEs need further
investigation. Despite the fact that GCs
improve functional status and reduce
radiographic erosions, it is imperative
that we place their long term side effects
into the therapeutic equation in order to
determine their appropriate place in our
treatment armamentarium.
CONCLUSION
There is thus clear evidence that GCs
improve physical function and reduce
progression of joint damage in the
treatment of RA. However, it cannot be
emphasised enough that the cautious
use of GCs in patients with longstanding
RA should be weighed and balanced for
the individual patient. A take home
message might be: ‘‘A little GC, like a
glass of wine, may benefit many (some
–(sic)) people, whereas a high dose of
GC, like a bottle of wine is harmful to
all’’.49 In both cases long term intake
might be harmful.
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